Helen Susan Kim
CIK 1422772 · EVP, Business Development · last filed 2026-01-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$117.65M
Companies
9
Total Filings
45
Lifetime Open-Market Net
-$14.34M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKTS | Director | 4,859,370 | $24.21 | $117.65M | $15.03M | 1 | 2026-01-12 |
| PRTA | Director | — | $8.70 | — | $0 | 4 | 2025-05-16 |
| Applied Molecular Transport Inc. (AMTI) Delisted | Director | 575,951 | $0.26 | $151.5K | -$9.42M | 5 | 2021-08-27 |
| ASMB | Director | — | $25.91 | — | $0 | 4 | 2020-06-15 |
| XCUR | Director | — | $1.75 | — | $0 | 1 | 2020-06-08 |
| Kite Pharma, Inc. (KITE) Delisted | EVP, Business Development | 24,864 | — | — | -$19.98M | 12 | 2017-09-27 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | Director | — | $18.62 | — | $0 | 8 | 2015-07-01 |
| ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted | Director | — | — | — | $0 | 2 | 2013-09-24 |
| KOSAN BIOSCIENCES INC (KOSN) Delisted | President and CEO | 10,280 | — | — | $26.6K | 3 | 2008-04-02 |
Recent Filings · Page 2 of 5
45 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-15 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2020-06-08 | XCUR | Grant (A) | — | $0 | EDGAR |
| 2019-06-14 | — | Grant (A) | — | $0 | |
| 2019-05-17 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2018-06-21 | — | Grant (A) | — | $0 | |
| 2018-06-01 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2018-03-12 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2017-10-05 | — | Mixed | −21,693 | -$754.7K | |
| 2017-09-28 | — | Grant (A) | — | $0 | |
| 2017-09-27 | Kite Pharma, Inc. (KITE) Delisted | Mixed | +2,829 | -$569.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.